A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India

CompletedOBSERVATIONAL
Enrollment

388

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

June 3, 2024

Study Completion Date

June 3, 2024

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Oral semaglutide

Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY